PMID-18753666 – Pramlintide Weight Loss 12-Month Obesity Trial
Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816-1823.
Quick Reference
| Property | Value |
|---|---|
| PMID | 18753666 |
| DOI | 10.2337/dc08-0029 |
| Year | 2008 |
| Journal | Diabetes Care |
| Study Type | RCT (Phase 2) |
| Evidence Level | II |
| Sample | n=411 obese adults without diabetes (BMI 30-50 kg/m2) |
| Peptide(s) Studied | Pramlintide |
Key Findings
- Pramlintide 120 mcg, 240 mcg, and 360 mcg TID all produced significantly greater weight loss than placebo at 4 months
- At 12 months, pramlintide 360 mcg TID achieved approximately 6-8 kg total body weight loss
- Weight loss was progressive throughout the treatment period, not plateauing at 6 months as seen with many anti-obesity drugs
- 31% of pramlintide-treated subjects achieved >=5% body weight loss
- Weight loss was enhanced when combined with lifestyle modification (diet + exercise counseling)
- Nausea was dose-dependent, transient, and occurred primarily in the first 2-4 weeks
- No cardiovascular safety concerns; improvements in waist circumference observed
Study Design
Randomized, double-blind, placebo-controlled trial in obese adults (BMI 30-50 kg/m2) without diabetes. Participants received pramlintide at escalating doses (120, 240, or 360 mcg) or placebo three times daily before meals, combined with standardized lifestyle intervention (reduced-calorie diet + exercise). Primary endpoint was body weight change at 4 months, with a 12-month extension.
Limitations
- High dropout rate (~50% at 12 months)
- Three-times-daily injection regimen is burdensome for compliance
- Dose escalation was required to manage nausea, complicating initial treatment
- Study population excluded patients with diabetes (limits generalizability to T2D)
- The 6-8 kg weight loss is modest compared to modern GLP-1 RAs
Clinical Relevance
This trial provided pivotal proof-of-concept that the amylin pathway can produce clinically meaningful weight loss in obese non-diabetic adults. The progressive, non-plateauing weight loss pattern was noteworthy and suggested sustained biological effect. Despite the modest weight loss by today's standards (compared to semaglutide's 15% or tirzepatide's 20%+), this trial validated the amylin satiety mechanism for obesity treatment. The three-times-daily injection burden was a major limitation that next-generation amylin analogs like Cagrilintide (once weekly) were designed to overcome.
Related
#research #RCT #evidence-level-II #metabolic #pramlintide